13F Holdings
中文EN

ABEO ABEONA THERAPEUTICS INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 318306 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-175.9%
TTM EPS YoY-189.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin65.1%
Operating margin-186.1%
Net margin-160.3%
FCF margin-170.1%
EBITDA margin-178.5%

Returns

ROE-42.1%
ROA-31.0%
ROIC (approx.)-59.9%
Asset turnover0.19x

Leverage & solvency

Liabilities / assets26.8%
Debt / equity0.19x
Current ratio5.69x
Interest coverage-24.47x

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio0.5%
Payout ratio—
Capex / revenue7.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$5.82M—$3.50M$1.41M$3.00M
Cost of revenue$1.53M————
Gross profit$4.29M————
R&D expense$26.81M$34.36M$31.09M$28.96M$38.73M
SG&A expense$65.03M$29.85M$19.00M$17.26M$21.64M
Operating income-$89.45M-$64.21M-$47.13M-$50.91M-$89.84M
Interest expense$3.74M$4.21M$418,000$736,000$3.66M
Pretax income$71.28M-$63.73M———
Income tax$100,000————
Net income$71.18M-$63.73M-$54.19M-$39.70M-$84.94M
EBITDA-$86.90M-$62.21M-$44.85M-$47.82M-$86.59M
EPS (basic)1.34-1.55-2.53-5.53-21.57
EPS (diluted)1.01-1.55-2.53-5.53-0.86
Weighted avg. shares (diluted)66.14M41.05M21.38M7.86M98.44M
Balance sheet
Cash & equivalents$78.44M$23.36M$14.47M$14.22M$32.94M
Short-term investments$112.97M$74.36M$37.75M$37.93M$12.09M
Receivables$6.15M———$3.00M
Inventory$5.49M————
Current assets$204.91M$100.85M$55.74M$53.10M$56.29M
PP&E, net$9.92M$4.43M$3.53M$5.74M$12.34M
Intangibles———$0$1.38M
Total assets$219.57M$108.93M$64.00M$64.21M$79.59M
Current liabilities$29.57M$16.59M$13.42M$7.78M$16.62M
Short-term debt$12.22M$5.93M———
Long-term debt$7.81M$13.04M———
Total debt$20.04M$18.96M———
Total liabilities$60.35M$64.90M$49.18M$37.45M$37.22M
Shareholders' equity$159.22M$44.03M$14.83M$26.76M$42.37M
Net debt-$58.40M-$4.39M———
Shares outstanding55.04M45.64M26.52M17.72M5.89M
Cash flow statement
Operating cash flow-$76.33M-$56.02M-$37.01M-$43.48M-$65.67M
Capital expenditure$7.97M$2.45M$331,000$130,000$4.15M
Free cash flow-$84.30M-$58.46M-$37.34M-$43.61M-$69.82M
Investing cash flow$105.03M-$39.24M$208,000-$23.96M$66.06M
Financing cash flow$26.04M$104.14M$37.06M$43.17M$24.86M
Depreciation & amortization$2.55M$2.00M$2.29M$3.09M$3.25M
Stock-based compensation$10.78M$6.63M$4.77M$3.05M$8.92M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.